Lumicell is developing the LUM System, an integrated platform combining a fluorescent optical contrast agent, a handheld imaging device with single-cell detection, and proprietary decision software to guide surgeons in real time. The system is designed to detect and help remove residual cancer cells in the surgical cavity beyond the specimen margin, with the goal of reducing repeat surgeries and improving outcomes. Lumicell is investigating the LUM System in breast, prostate, colorectal, esophageal, and pancreatic cancer surgeries, with planned future indications including lung, ovarian, and brain cancers. The company highlights single-cell detection capability and instant image display to guide surgical removal. Advancement of the clinical pipeline and completion of breast cancer studies will be funded by a recently closed Series C financing.

Total raised

$29M

Funding rounds

1

Latest round

Series C

Latest activity

Dec 2017